Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses

BMC Microbiology

Yi Zeng²  Wang Sheng²  Xin Sun⁵  Paul KS Chan³  Shan Cen¹  Yuming Huang⁴  Xiangqian Xiao²  Wei Liu²  Yu Bai²  Miao Zhao² 

[1] Department of Virology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing PR China;College of Life Science and Bioengineering, Beijing University of Technology, 100, Pingleyuan, Chaoyang District, Beijing 100124, PR China;Department of Microbiology, Chinese University of Hong Kong, Hong Kong PR China;Department of Neurology, Beijing Ditan Hospital, Capital Medical University, Beijing PR China;Research Center for Life Science, Beihua University, 3999, Binjiangdong Road, Jinlin, Jilin Province 132013, PR China

关键词: Chimeric virus-like particle;    Peptide;    VP4;    Vaccine;    Enterovirus 71;   

Others  :  1142411
DOI  :  10.1186/1471-2180-13-287

 received in 2013-09-20, accepted in 2013-12-02,  发布年份 2013

【 摘 要 】

Background

Enterovirus 71 (EV71) is major cause of hand, foot and mouth disease. Large epidemics of EV71 infection have been recently reported in the Asian-Pacific region. Currently, no vaccine is available to prevent EV71 infection.

Results

The peptide (VP4N20) consisting of the first 20 amino acids at the N-terminal of VP4 of EV71 genotype C4 were fused to hepatitis B core (HBcAg) protein. Expression of fusion proteins in E. coli resulted in the formation of chimeric virus-like particles (VLPs). Mice immunized with the chimeric VLPs elicited anti-VP4N20 antibody response. In vitro microneutralization experiments showed that anti-chimeric VLPs sera were able to neutralize not only EV71 of genotype C4 but also EV71 of genotype A. Neonatal mice model confirmed the neutralizing ability of anti-chimeric VLPs sera. Eiptope mapping led to the identification of a “core sequence” responsible for antibody recognition within the peptide.

Conclusions

Immunization of chimeric VLPs is able to elicit antibodies displaying a broad neutralizing activity against different genotypes of EV71 in vitro. The “core sequence” of EV71-VP4 is highly conserved across EV71 genotypes. The chimeric VLPs have a great potential to be a novel vaccine candidate with a broad cross-protection against different EV71 genotypes.

【 授权许可】

   
2013 Zhao et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Schmidt NJ, Lennette EH, Ho HH: An Apparently New Enterovirus Isolated from Patients with Disease of the Central Nervous System. J Infect Dis 1974, 129(3):304-309.
• [2]Brown BA, Pallansch MA: Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res 1995, 39(2–3):195-205.
• [3]Chung Y-C, Ho M-S, Wu J-C, Chen W-J, Huang J-H, Chou S-T, Hu Y-C: Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008, 26(15):1855-1862.
• [4]Tuthill T, Groppelli E, Hogle J, Rowlands D: Picornaviruses. In Cell Entry by Non-Enveloped Viruses. 343rd edition. Edited by Johnson JE. Germany: Springer Berlin Heidelberg; 2010:43-89.
• [5]Chow M, Newman JFE, Filman D, Hogle JM, Rowlands DJ, Brown F: Myristylation of picornavirus capsid protein VP4 and its structural significance. Nature 1987, 327(6122):482-486.
• [6]Lewis JK, Bothner B, Smith TJ, Siuzdak G: Antiviral agent blocks breathing of the common cold virus. Proc Natl Acad Sci 1998, 95(12):6774-6778.
• [7]Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta C, et al.: A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 2012, 19(4):424-429.
• [8]McMinn PC: An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 2002, 26(1):91-107.
• [9]Suzuki Y, Taya K, Nakashima K, Ohyama T, Kobayashi JM, Ohkusa Y, Okabe N: Risk factors for severe hand foot and mouth disease. Pediatr Int 2010, 52(2):203-207.
• [10]Guan D, van der Sanden S, Zeng H, Li W, Zheng H, Ma C, Su J, Liu Z, Guo X, Zhang X, et al.: Population Dynamics and Genetic Diversity of C4 Strains of Human Enterovirus 71 in Mainland China, 1998–2010. PLoS ONE 2012, 7(9):e44386.
• [11]Wu Y, Yeo A, Phoon MC, Tan EL, Poh CL, Quak SH, Chow VTK: The largest outbreak of hand; foot and mouth disease in Singapore in 2008: The role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis 2010, 14(12):e1076-e1081.
• [12]Iwai M, Masaki A, Hasegawa S, Obara M, Horimoto E, Nakamura K, Tanaka Y, Endo K, Tanaka K, Ueda J, et al.: Genetic changes of coxsackievirus A16 and enterovirus 71 isolated from hand, foot, and mouth disease patients in Toyama, Japan between 1981 and 2007. Japanese journal of infectious diseases 2009, 62(4):254-259.
• [13]Chen S-C, Chang H-L, Yan T-R, Cheng Y-T, Chen K-T: An Eight-Year Study of Epidemiologic Features of Enterovirus 71 Infection In Taiwan. AmJTrop Med Hyg 2007, 77(1):188-191.
• [14]Chen K-T, Chang H-L, Wang S-T, Cheng Y-T, Yang J-Y: Epidemiologic Features of Hand-Foot-Mouth Disease and Herpangina Caused by Enterovirus 71 in Taiwan, 1998–2005. Pediatrics 2007, 120(2):e244-e252.
• [15]Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH: Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010, 10(11):778-790.
• [16]Liu C-C, Chou A-H, Lien S-P, Lin H-Y, Liu S-J, Chang J-Y, Guo M-S, Chow Y-H, Yang W-S, Chang KH-W, et al.: Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine 2011, 29(26):4362-4372.
• [17]Chang GH, Luo YJ, Wu XY, Si BY, Lin L, Zhu QY: Monoclonal antibody induced with inactived EV71-Hn2 virus protects mice against lethal EV71-Hn2 virus infection. Virology journal 2010, 7:106. BioMed Central Full Text
• [18]Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL: Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res 2007, 125(1):61-68.
• [19]Foo DG, Alonso S, Chow VT, Poh CL: Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes and infection/Institut Pasteur 2007, 9(11):1299-1306.
• [20]Liu JN, Wang W, Duo JY, Hao Y, Ma CM, Li WB, Lin SZ, Gao XZ, Liu XL, Xu YF, et al.: Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 2010, 28(46):7444-7451.
• [21]Yoke-Fun C, AbuBakar S: Phylogenetic evidence for inter-typic recombination in the emergence of human enterovirus 71 subgenotypes. BMC microbiology 2006, 6:74. BioMed Central Full Text
• [22]Huang SW, Kiang D, Smith DJ, Wang JR: Evolution of re-emergent virus and its impact on enterovirus 71 epidemics. Experimental biology and medicine (Maywood, NJ) 2011, 236(8):899-908.
• [23]Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR, Shih SR: An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. The New England journal of medicine 1999, 341(13):929-935.
• [24]Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, Mao N, Xu S, Zhu S, Cui A, et al.: An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virology journal 2010, 7:94. BioMed Central Full Text
• [25]Zhang Y, Tan X, Cui A, Mao N, Xu S, Zhu Z, Zhou J, Shi J, Zhao Y, Wang X, et al.: Complete genome analysis of the C4 subgenotype strains of enterovirus 71: predominant recombination C4 viruses persistently circulating in China for 14 years. PLoS One 2013, 8(2):e56341.
• [26]Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS: Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2001, 20(5–6):895-904.
• [27]Chung CY, Chen CY, Lin SY, Chung YC, Chiu HY, Chi WK, Lin YL, Chiang BL, Chen WJ, Hu YC: Enterovirus 71 virus-like particle vaccine: improved production conditions for enhanced yield. Vaccine 2010, 28(43):6951-6957.
• [28]Tung WS, Bakar SA, Sekawi Z, Rosli R: DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genetic vaccines and therapy 2007, 5:6. BioMed Central Full Text
• [29]Chiu CH, Chu C, He CC, Lin TY: Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes and infection/Institut Pasteur 2006, 8(7):1671-1678.
• [30]Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, Mizuta K, Iwasaki T, Sata T, Wakita T, Shimizu H: An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. Journal of virology 2007, 81(17):9386-9395.
• [31]Dong C, Wang J, Liu L, Zhao H, Shi H, Zhang Y, Jiang L, Li Q: Optimized development of a candidate strain of inactivated EV71 vaccine and analysis of its immunogenicity in rhesus monkeys. Human vaccines 2010, 6(12):1028-1037.
• [32]Liu L, Zhang Y, Wang J, Zhao H, Jiang L, Che Y, Shi H, Li R, Mo Z, Huang T, et al.: Study of the integrated immune response induced by an inactivated EV71 vaccine. PLoS One 2013, 8(1):e54451.
• [33]Dong C, Liu L, Zhao H, Wang J, Liao Y, Zhang X, Na R, Liang Y, Wang L, Li Q: Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine 2011, 29(37):6269-6275.
• [34]Bek EJ, Hussain KM, Phuektes P, Kok CC, Gao Q, Cai F, Gao Z, McMinn PC: Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine 2011, 29(29–30):4829-4838.
• [35]Brown BA, Oberste MS, Alexander JP Jr, Kennett ML, Pallansch MA: Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. Journal of virology 1999, 73(12):9969-9975.
• [36]Roivainen M, Piirainen L, Ryä T, Närvänen A, Hovi T: An Immunodominant N-Terminal Region of VP1 Protein of Poliovirion That Is Buried in Crystal Structure Can Be Exposed in Solution. Virology 1993, 195(2):762-765.
• [37]Li Q, Yafal AG, Lee YM, Hogle J, Chow M: Poliovirus neutralization by antibodies to internal epitopes of VP4 and VP1 results from reversible exposure of these sequences at physiological temperature. J Virol 1994, 68(6):3965-3970.
• [38]Katpally U, Fu TM, Freed DC, Casimiro DR, Smith TJ: Antibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralization. Journal of virology 2009, 83(14):7040-7048.
• [39]Hogle J, Chow M, Filman D: Three-dimensional structure of poliovirus at 2.9 A resolution. Science 1985, 229(4720):1358-1365.
• [40]Fricks CE, Hogle JM: Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding. J Virol 1990, 64(5):1934-1945.
• [41]Greve JM, Forte CP, Marlor CW, Meyer AM, Hoover-Litty H, Wunderlich D, McClelland A: Mechanisms of receptor-mediated rhinovirus neutralization defined by two soluble forms of ICAM-1. J Virol 1991, 65(11):6015-6023.
• [42]Davis MP, Bottley G, Beales LP, Killington RA, Rowlands DJ, Tuthill TJ: Recombinant VP4 of human rhinovirus induces permeability in model membranes. Journal of virology 2008, 82(8):4169-4174.